Phenomix Sciences

Phenomix Sciences

Private
Menlo Park, CaliforniaHealthcare & Life Scienceshttps://www.phenomixsciences.com

Last Round

Series A

May 16, 2024

Total Funding Raised

$9.8M

Company Overview

Phenomix Sciences is a biotechnology company that develops a data analysis platform for precision medicine in obesity management, featuring a novel blood test and an AI-driven algorithm to classify patients' unique pathophysiological phenotypes.

Sector

Healthcare & Life Sciences

Verticals

Precision Medicine, Biotechnology, Medical AI, Healthcare Analytics, Clinical Trials

Business Model

B2B

Customer Profile

Services & Consulting, Data as a Service, Government Contracts

AI Layer

Application

Keywords

obesity phenotypingpersonalized obesity treatmentgenetic testprecision obesity careGLP-1 response predictionobesity genetic testweight loss DNA testpharmacogenomicsclinical decision supportobesity diagnosticssaliva testtelehealth diagnosticsclinical trial supportMayo Clinic spinout

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Phenomix Sciences Comps

Public and private peers based on sector, stage, and business model.

CompanyStatusEst. ValuationRev Multiple
OpenAIPrivate$86.0B~40x
CoherePrivate$5.0B--
Competitor 1Public$XX.XBXXx
Competitor 2Public$XX.XBXXx

View Full Comps Set

Access detailed peer comparisons, multiples, and valuation benchmarks.

Phenomix Sciences Funding Rounds

Historical fundraising activity

RoundDateAmount RaisedValuationInvestorsSources
Series AMay 16, 2024
GrantMay 16, 2024
GrantMar 15, 2024
SeedMar 22, 2021
SeedNov 16, 2018

Key People

Founding team and executive leadership

Mark Bagnall

Chief Executive Officer

Executive Team

Frank Grazzini

CFO

Executive Team

Liv Williamsen

Chief Operating Officer

Executive Team

Phenomix Sciences Investors

Notable investors and investment history

Market signals

Structured signals derived from secondary market and firmographic data.

  • Nov 4, 2025

    MyPhenome test shows clinical utility in predicting obesity and treatment outcomes.

  • Nov 4, 2025

    Presented new research at Obesity Week 2025.

Phenomix Sciences Filings

SEC and related filings with document metadata.

TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

Phenomix Sciences Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about Phenomix Sciences's valuation, stock price, and market status.

Firmographic Details

HeadquartersMenlo Park, California
Employee Range15
Year Founded2021
Last FundingMay 16, 2024

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.







Disclaimer All investments involve risk, including the risk of loss of principal. You should carefully consider your investment objectives, risks, transaction costs and other expenses before deciding to invest in options, swaps or other investments.This does not constitute an offer by Caplight Technologies, Inc. to sell, or a solicitation of an offer to buy, any securities and may not be used or relied upon in connection with any offer or sale of securities. An offer or solicitation can be made only through the delivery of final offering document(s) and purchase agreement(s), and will be subject to the terms and conditions and risks delivered in such documents. Any securities offered are offered through Caplight Markets LLC, member FINRA/SIPC.